Neophyr (Nitric Oxide)

Nitric Oxide, the active ingredient in Neophyr, is a gaseous signaling molecule presented as an inhalation therapy for respiratory support in patients with pulmonary vascular disorders. It acts locally in the lungs to promote selective vasodilation and improve oxygenation.

GNH USA supplies Neophyr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across EU and global markets. Our distribution network adheres to stringent handling standards for inhalation products.

Neophyr, delivered by inhalation, is used in conditions involving pulmonary vascular dysfunction.

Neonatal Pulmonary Hypertension: improves oxygenation and reduces the need for extracorporeal support. Acute Respiratory Distress Syndrome (ARDS): provides selective pulmonary vasodilation to enhance ventilation‑perfusion matching. Pulmonary Hypertension: lowers pulmonary arterial pressure and improves exercise capacity.

Inhaled nitric oxide may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Headache - Dizziness - Nausea - Flushing - Mild hypotension - Low‑grade methemoglobinemia

Serious or Rare Side Effects: - Severe hypotension - Rebound pulmonary hypertension upon abrupt discontinuation - High‑level methemoglobinemia (>10%) - Nitrogen dioxide toxicity from oxidation of nitric oxide - Acute respiratory distress or worsening hypoxemia

When prescribing Neophyr, clinicians should consider several safety precautions to minimize risk.

Pregnancy: use only if potential benefit justifies potential risk to the fetus. Breastfeeding: caution, as nitric oxide may be transferred to the infant. Renal impairment: monitor for accumulation of metabolites. Methemoglobinemia risk: avoid in patients with pre‑existing elevated methemoglobin levels. Severe anemia: use with caution due to reduced oxygen‑carrying capacity. Store at ambient temperature: keep in original container, protect from moisture and light.

Nitric oxide inhalation can interact with other agents, altering its efficacy or safety profile.

Major Interactions (Avoid): - Phosphodiesterase inhibitors (e.g., sildenafil): additive vasodilation may cause severe hypotension. - Inhaled anesthetics (e.g., nitrous oxide): increased risk of methemoglobinemia.

Moderate Interactions (Monitor Closely): - Bronchodilators (e.g., albuterol): may enhance vasodilatory effect, requiring blood pressure monitoring. - Antioxidants (e.g., vitamin C): may reduce nitric oxide availability, potentially diminishing therapeutic response. - Blood transfusions: can affect methemoglobin levels, necessitating laboratory monitoring.